InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City
September 04, 2018 07:30 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018
August 06, 2018 16:05 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence
July 23, 2018 08:41 ET
|
InspireMD, Inc.
Tel Aviv, Israel, July 23, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering
June 29, 2018 10:24 ET
|
InspireMD, Inc.
Tel Aviv, Israel, June 29, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD’s CGuard EPS Featured at the SBHCI Congress in Brazil
June 20, 2018 07:20 ET
|
InspireMD, Inc.
Tel Aviv, Israel, June 20, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress
June 11, 2018 09:53 ET
|
InspireMD, Inc.
Tel Aviv, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS
May 30, 2018 07:31 ET
|
InspireMD, Inc.
Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months TEL AVIV, ISRAEL, May 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE...
InspireMD Receives Regulatory Approval for both CGuard EPS™ and MGuard Prime™ in Ecuador
May 16, 2018 08:12 ET
|
InspireMD, Inc.
Tel Aviv, Israel, May 16, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Reports 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018
May 07, 2018 16:05 ET
|
InspireMD, Inc.
Tel Aviv, Israel, May 07, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Schedules First Quarter 2018 Earnings Conference Call
May 01, 2018 07:00 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL , May 01, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...